Savior Lifetec Corporation (4167.TWO)
TWD 18.95
(-4.53%)
TWD 18.95
(-4.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.42 Million TWD | -104.65% |
| 2022 | 52 Million TWD | 110.76% |
| 2021 | 24.67 Million TWD | -91.4% |
| 2020 | 287.04 Million TWD | 739.84% |
| 2019 | 34.17 Million TWD | 109.55% |
| 2018 | -357.82 Million TWD | -437.6% |
| 2017 | 105.99 Million TWD | 157.9% |
| 2016 | -183.05 Million TWD | 60.49% |
| 2015 | -463.33 Million TWD | -39.23% |
| 2014 | -332.78 Million TWD | -49.43% |
| 2013 | -222.7 Million TWD | 49.93% |
| 2012 | -444.76 Million TWD | -49.52% |
| 2011 | -297.46 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 30.87 Million TWD | -57.05% |
| 2024 Q1 | 71.89 Million TWD | -9.24% |
| 2023 Q3 | -14.95 Million TWD | -309.32% |
| 2023 Q4 | 79.22 Million TWD | 629.69% |
| 2023 FY | -2.42 Million TWD | -104.65% |
| 2023 Q1 | -1.28 Million TWD | 96.57% |
| 2023 Q2 | 7.14 Million TWD | 656.46% |
| 2022 FY | 52 Million TWD | 110.76% |
| 2022 Q4 | -37.48 Million TWD | -127.57% |
| 2022 Q2 | 2.96 Million TWD | 106.01% |
| 2022 Q3 | 135.95 Million TWD | 4479.22% |
| 2022 Q1 | -49.43 Million TWD | -97.85% |
| 2021 Q3 | -63.5 Million TWD | -284.36% |
| 2021 Q1 | 85.21 Million TWD | -24.33% |
| 2021 FY | 24.67 Million TWD | -91.4% |
| 2021 Q2 | 34.44 Million TWD | -59.58% |
| 2021 Q4 | -24.98 Million TWD | 60.66% |
| 2020 FY | 287.04 Million TWD | 739.84% |
| 2020 Q3 | 60.49 Million TWD | 91.92% |
| 2020 Q2 | 31.52 Million TWD | -16.63% |
| 2020 Q1 | 37.8 Million TWD | -38.67% |
| 2020 Q4 | 112.61 Million TWD | 86.16% |
| 2019 Q2 | -16.74 Million TWD | -555.4% |
| 2019 Q4 | 61.64 Million TWD | 341.53% |
| 2019 Q3 | 13.96 Million TWD | 183.38% |
| 2019 FY | 34.17 Million TWD | 109.55% |
| 2019 Q1 | 3.67 Million TWD | 103.34% |
| 2018 FY | -357.82 Million TWD | -437.6% |
| 2018 Q4 | -110.2 Million TWD | -19.36% |
| 2018 Q3 | -92.32 Million TWD | -43.99% |
| 2018 Q2 | -64.12 Million TWD | 29.67% |
| 2018 Q1 | -91.17 Million TWD | -198.33% |
| 2017 FY | 105.99 Million TWD | 157.9% |
| 2017 Q3 | 22.27 Million TWD | -69.97% |
| 2017 Q1 | 40.09 Million TWD | 118.36% |
| 2017 Q2 | 74.17 Million TWD | 85.0% |
| 2017 Q4 | -30.56 Million TWD | -237.18% |
| 2016 Q4 | 18.36 Million TWD | 146.63% |
| 2016 FY | -183.05 Million TWD | 60.49% |
| 2016 Q1 | -109.54 Million TWD | 29.96% |
| 2016 Q3 | -39.37 Million TWD | 24.99% |
| 2016 Q2 | -52.49 Million TWD | 52.08% |
| 2015 Q4 | -156.41 Million TWD | -45.65% |
| 2015 Q3 | -107.38 Million TWD | -12.09% |
| 2015 FY | -463.33 Million TWD | -39.23% |
| 2015 Q2 | -95.8 Million TWD | 7.63% |
| 2015 Q1 | -103.72 Million TWD | 34.82% |
| 2014 Q3 | -88.07 Million TWD | -52.43% |
| 2014 FY | -332.78 Million TWD | -49.43% |
| 2014 Q4 | -159.12 Million TWD | -80.66% |
| 2014 Q2 | -57.78 Million TWD | 11.68% |
| 2014 Q1 | -65.42 Million TWD | 17.48% |
| 2013 Q1 | -46.78 Million TWD | 55.09% |
| 2013 Q4 | -79.27 Million TWD | -59.04% |
| 2013 FY | -222.7 Million TWD | 49.93% |
| 2013 Q3 | -49.84 Million TWD | -6.54% |
| 2013 Q2 | -46.78 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 FY | -444.76 Million TWD | -49.52% |
| 2012 Q4 | -104.17 Million TWD | 0.0% |
| 2012 Q3 | -104.17 Million TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | -297.46 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| SYN-TECH Chem. & Pharm. Co., Ltd. | 281.85 Million TWD | 100.859% |
| Level Biotechnology Inc. | 67.55 Million TWD | 103.582% |
| TaiMed Biologics Inc. | -166.23 Million TWD | 98.544% |
| GlycoNex Incorporation | -259.86 Million TWD | 99.069% |
| GeneReach Biotechnology Corp. | -229.28 Million TWD | 98.945% |
| OBI Pharma, Inc. | -2.08 Billion TWD | 99.884% |
| Taiwan Advance Bio-Pharmaceutical Inc. | -2.25 Million TWD | -7.412% |
| Genomics BioSci & Tech. Co.,Ltd. | -84.99 Million TWD | 97.153% |
| Visgeneer Inc. | -21.15 Million TWD | 88.563% |
| Neith Corporation | -48.85 Million TWD | 95.046% |
| Lumosa Therapeutics Co., Ltd. | -375.62 Million TWD | 99.356% |
| Medigen Vaccine Biologics Corporation | -1.21 Billion TWD | 99.801% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -6.61 Million TWD | 63.389% |
| Enimmune corporation | -243.47 Million TWD | 99.006% |
| TaiRx, Inc. | -214.69 Million TWD | 98.873% |
| CHO Pharma, Inc. | -268.99 Million TWD | 99.1% |
| BioLASCO Taiwan Co., Ltd. | 63.33 Million TWD | 103.821% |
| Sunny Pharmtech Inc. | -72.09 Million TWD | 96.643% |
| Ever Supreme Bio Technology Co., Ltd | 337.73 Million TWD | 100.717% |
| Feng Chi Biotech Corp. | 24.16 Million TWD | 110.016% |
| Lukas Biomedical Inc. | -43.56 Million TWD | 94.444% |
| RBC Bioscience Corporation | 14.53 Million TWD | 116.645% |
| NaviFUS Corp. | -76.42 Million TWD | 96.834% |
| BRIM Biotechnology, Inc. | -694.12 Million TWD | 99.651% |
| Shine-On BioMedical Co.,Ltd. | -62.68 Million TWD | 96.139% |
| Great Novel Therapeutics Biotech & Medicals | -65.81 Million TWD | 96.323% |
| Sagittarius Life Science Corp | -64.37 Million TWD | 96.241% |
| Bio Preventive Medicine Corp. | -70.58 Million TWD | 96.571% |
| Advagene Biopharma Co., Ltd. | -93.33 Million TWD | 97.407% |
| BioGend Therapeutics Co., Ltd. | -176.54 Million TWD | 98.629% |
| G&E Herbal Biotechnology Co., Ltd. | 80.68 Million TWD | 102.999% |
| Andros Pharmaceuticals Co.,Ltd | -67.69 Million TWD | 96.425% |
| Lin BioScience, Inc. | -1.09 Billion TWD | 99.779% |
| Anti-Microbial Savior BioteQ Co., Ltd | -56.74 Million TWD | 95.736% |
| AP Biosciences Inc | -347.47 Million TWD | 99.304% |
| Sunmax Biotechnology Co., Ltd. | 894.79 Million TWD | 100.27% |
| Syngen Biotech Co.,Ltd. | 334.08 Million TWD | 100.724% |
| EirGenix Inc. | -1.03 Billion TWD | 99.765% |
| Pharmosa Biopharm Inc. | -2.82 Million TWD | 14.306% |
| Mycenax Biotech Inc. | -602.1 Million TWD | 99.598% |
| SynCore Biotechnology Co.,Ltd | -45.5 Million TWD | 94.682% |
| Eusol Biotech Co.,Ltd. | -41.48 Million TWD | 94.166% |
| NeoCore Technology Co., Ltd. | -84.94 Million TWD | 97.151% |
| VBI | -16.13 Million TWD | 84.999% |
| BiOptic Inc. | 44.05 Million TWD | 105.493% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -93.95 Million TWD | 97.424% |
| Sinew Pharma Inc. | -186.25 Million TWD | 98.701% |
| Greenyn Biotechnology Co., Ltd | 159.81 Million TWD | 101.514% |
| Medigen Biotechnology Corp. | -1.23 Billion TWD | 99.804% |
| 3D Global Biotech Inc. | -62.85 Million TWD | 96.15% |
| Intech Biopharm Corporation | -304.39 Million TWD | 99.205% |
| Oneness Biotech Co., Ltd. | -1.09 Billion TWD | 99.779% |
| TWi Biotechnology, Inc. | -169.55 Million TWD | 98.573% |
| TCI GENE Inc. | 10.04 Million TWD | 124.082% |
| MegaPro Biomedical Co., Ltd | -127.25 Million TWD | 98.098% |
| Senhwa Biosciences, Inc. | -311.11 Million TWD | 99.222% |
| Taiwan Bio Therapeutics Co., Ltd | -212.2 Million TWD | 98.86% |
| NatureWise Biotech & Medicals Corporation | 3.43 Million TWD | 170.472% |
| PharmaEngine, Inc. | 277.18 Million TWD | 100.873% |
| TaiGen Biopharmaceuticals Holdings Limited | -174.69 Million TWD | 98.615% |
| Meribank Biotech Co., Ltd | -123.15 Million TWD | 98.035% |
| Acepodia, Inc. | -435.97 Million TWD | 99.445% |
| Caliway Biopharmaceuticals Co., Ltd. | -487.95 Million TWD | 99.504% |